Codexis (NASDAQ:CDXS) Stock Price Up 9.3% on Strong Earnings

Codexis, Inc. (NASDAQ:CDXSGet Rating)’s stock price rose 9.3% during trading on Friday following a better than expected earnings announcement. The company traded as high as $8.79 and last traded at $8.72. Approximately 53,025 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 1,771,744 shares. The stock had previously closed at $7.98.

The biotechnology company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.08. The business had revenue of $38.41 million during the quarter, compared to the consensus estimate of $37.86 million. Codexis had a negative return on equity of 12.56% and a negative net margin of 16.85%. The business’s quarterly revenue was up 50.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.07) EPS.

Wall Street Analysts Forecast Growth

CDXS has been the subject of several research analyst reports. HC Wainwright reduced their target price on Codexis from $38.00 to $27.00 in a research note on Monday, July 18th. Piper Sandler reduced their price objective on Codexis from $35.00 to $22.00 and set an “overweight” rating for the company in a research note on Thursday, July 14th. Cowen reduced their price objective on Codexis from $39.00 to $21.00 and set an “outperform” rating for the company in a research note on Friday, July 15th. Craig Hallum reduced their price objective on Codexis from $42.00 to $19.00 in a research note on Friday, July 15th. Finally, Cowen reduced their price objective on Codexis from $39.00 to $21.00 in a research note on Friday, July 15th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $21.67.

Insider Buying and Selling at Codexis

In other Codexis news, CEO John J. Nicols sold 38,500 shares of the company’s stock in a transaction on Thursday, May 12th. The stock was sold at an average price of $10.31, for a total value of $396,935.00. Following the completion of the sale, the chief executive officer now directly owns 1,022,679 shares in the company, valued at approximately $10,543,820.49. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 7.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Codexis

A number of hedge funds have recently modified their holdings of the business. Baillie Gifford & Co. grew its holdings in shares of Codexis by 2.8% during the 1st quarter. Baillie Gifford & Co. now owns 7,386,628 shares of the biotechnology company’s stock worth $152,312,000 after purchasing an additional 204,226 shares during the period. BlackRock Inc. grew its holdings in shares of Codexis by 0.7% during the 1st quarter. BlackRock Inc. now owns 5,183,443 shares of the biotechnology company’s stock worth $106,885,000 after purchasing an additional 38,494 shares during the period. ARK Investment Management LLC grew its holdings in shares of Codexis by 13.8% during the 2nd quarter. ARK Investment Management LLC now owns 4,486,573 shares of the biotechnology company’s stock worth $47,917,000 after purchasing an additional 543,936 shares during the period. Vanguard Group Inc. grew its holdings in shares of Codexis by 6.8% during the 1st quarter. Vanguard Group Inc. now owns 3,632,362 shares of the biotechnology company’s stock worth $74,899,000 after purchasing an additional 231,872 shares during the period. Finally, Nantahala Capital Management LLC grew its holdings in shares of Codexis by 5.3% during the 1st quarter. Nantahala Capital Management LLC now owns 3,383,049 shares of the biotechnology company’s stock worth $69,758,000 after purchasing an additional 168,952 shares during the period.

Codexis Trading Up 9.6 %

The firm has a market capitalization of $571.41 million, a PE ratio of -26.52 and a beta of 1.61. The business has a fifty day moving average price of $9.56 and a two-hundred day moving average price of $14.53.

About Codexis

(Get Rating)

Codexis, Inc discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services.

Further Reading

Want More Great Investing Ideas?

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.